Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edicotinib in Relapsed/Refractory AML
NCT03557970Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of edicotinib in acute myeloid leukemia (AML), sponsored by OHSU Knight Cancer Institute. Started Oct 2018; status: terminated.
02
Drugs
edicotinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03557970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557970.